Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Use of breast cancer risk reducing medications by breast cancer risk level in an older U.S. cohort

Cancer Epidemiology(2025)10.1016/j.canep.2025.102856Source: DataRank Database

Use of breast cancer risk reducing medications by breast cancer risk level in an older U.S. cohort is a research paper published in Cancer Epidemiology (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.00)OA: greenTopics (41)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Edward R. Sauter,Goli Samimi ORCID,Paul F. Pinsky ORCID

Live enrichment

PubMed:40451088 PMC:PMC12235552 OpenAlex:https://openalex.org/W4410921032

Intramural NIH HHS

Grant: Z99 CA999999

FWCI

0.00

Citation Percentile

0.1%

Influential Citations

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12235552/

publisherhttps://api.elsevier.com/content/article/PII:S187778212500116X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S187778212500116X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.canep.2025.102856

Fields of Study

BRCA gene mutations in cancerCancer Risks and FactorsEstrogen and related hormone effectsMedicineHumansFemaleBreast NeoplasmsAgedUnited StatesRaloxifene HydrochlorideTamoxifenAromatase InhibitorsAged, 80 and overCohort StudiesMedicare Part DRisk Assessment

MeSH Terms

AgedAged, 80 and overBreast NeoplasmsFemaleHumansTamoxifenUnited StatesCohort StudiesRisk AssessmentRaloxifene HydrochlorideAromatase InhibitorsMedicare Part D

Keywords

MedicineRaloxifeneBreast cancerTamoxifenCohortInternal medicineOncologyGynecologyPopulationCancerCohort studyChemopreventionHigh-risk

Sustainable Development Goals

SDG 0: Good health and well-being